The MarketReader Minute
đź’Š IBB Ticks Up as Gilead Gains FDA Nod for Groundbreaking HIV Prevention Shot | Biotech Sector Insights
(IBB) rose, buoyed by Gilead’s +2.1% jump after FDA approval of the first twice-yearly HIV prevention drug. Other IBB gainers include Regeneron, Vertex, and Sarepta, as markets absorb tariff risks and surging silver prices.